Table 3.

Immunogenicity of anti-IL-17, IL-12/23, and IL-23 mAbs in psoriatic arthritis

References	Product	Disease	ADAsa	Impact on serum concentration and clinical response	Reduced by methotrexate
[48, 49]	Secukinumab	Psoriasis	0.4% < 2%	No
[50]	Secukinumab	Chronic inflammatory diseases	< 1%
[51]	Secukinumab	PsA	0.35%	No
[52]	Ixekizumab	Psoriasis	17.4%	No
[53]	Ixekizumab	PsA	10.3–12%	No	No
[54, 55]	Bimekizumab	Psoriasis, PsA, SpA	31–57%b	No
[50]	Ustekinumab	Chronic inflammatory diseases	1–11%
[56]	Ustekinumab	PsA	18.9–35%	No	No
[57]	Guselkumab	Psoriasis	14.4–15.5%	No
[58]	Guselkumab	PsA	4.5%
[59]	Risankizumab	Psoriasis PsA	24% 12.1%	No No

ADAs anti-drug antibodies, IL interleukin, mAbs monoclonal antibodies, PsA psoriatic arthritis, SpA spondyloarthritis

^aHeterogeneity of dosing techniques

^bProbably with a very sensitive detection method